Re: Bladder Tumor Markers. E. M. Messing J Urol, 175: 1195-1196, 2006

Journal of Urology

Volumn 176, Issue 5, 2006, Pages 2308-

  Reid Pitts Jr , W ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; AROMATASE; ESTROGEN RECEPTOR; MOLECULAR MARKER; STEROID 5ALPHA REDUCTASE; TUMOR MARKER;

ADENOCARCINOMA; BLADDER TUMOR; CARCINOMA IN SITU; IMMUNOHISTOCHEMISTRY; LETTER; MEDICAL INFORMATICS; PRECANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SCORING SYSTEM; TREATMENT PLANNING; UROTHELIUM;

HUMANS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 33750299610     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.06.052     Document Type: Letter

References (2)

1. Barocas D.A., Kawamoto H., Dreizin D.F., Howard M.E., Choi J., Pitts W.R., et al. Five-alpha-reductase expression in benign and malignant urothelium: correlation with disease characteristics and outcome. Urology 66 (2005) 1134
2. Boorjian S., Ugras S., Mongan N.P., Gudas L.J., You X., Tickoo S.K., et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 64 (2004) 383